Shire PLC (NASDAQ:SHPG) has been given an average recommendation of “Hold” by the nineteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $218.00.

A number of brokerages have recently weighed in on SHPG. BidaskClub lowered shares of Shire from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein raised shares of Shire from a “market perform” rating to an “outperform” rating in a report on Wednesday. Royal Bank of Canada set a $192.00 price target on shares of Shire and gave the company a “buy” rating in a report on Monday, February 5th. Finally, Bank of America upped their price target on shares of Shire from $236.00 to $237.00 and gave the company a “buy” rating in a report on Monday, February 5th.

Several hedge funds have recently bought and sold shares of the company. Harding Loevner LP boosted its stake in shares of Shire by 18,894.4% during the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after acquiring an additional 126,865,607 shares in the last quarter. Boston Partners boosted its stake in shares of Shire by 60.9% during the 4th quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after acquiring an additional 886,572 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Shire by 35.3% during the 3rd quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock worth $266,613,000 after acquiring an additional 454,092 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Shire by 6.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after acquiring an additional 96,115 shares in the last quarter. Finally, Third Point LLC purchased a new stake in shares of Shire during the 3rd quarter worth about $183,768,000. 20.74% of the stock is currently owned by institutional investors and hedge funds.

Shares of Shire (NASDAQ SHPG) traded up $0.19 on Friday, hitting $132.86. 2,040,965 shares of the stock were exchanged, compared to its average volume of 1,529,570. The stock has a market capitalization of $40,190.00, a price-to-earnings ratio of 25.02, a PEG ratio of 0.71 and a beta of 1.41. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire has a 12-month low of $123.73 and a 12-month high of $192.15.

Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating analysts’ consensus estimates of $3.86 by $0.12. The firm had revenue of $4.15 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. Shire’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $3.37 earnings per share. equities research analysts forecast that Shire will post 15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Shire PLC (SHPG) Target Price at $217.27” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/02/14/brokerages-set-shire-plc-shpg-target-price-at-217-27.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.